Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 May 30;5(5):CD005010.
doi: 10.1002/14651858.CD005010.pub3.

Primary cryotherapy for localised or locally advanced prostate cancer

Jae Hung Jung  1 , Michael C Risk, Robert Goldfarb, Balaji Reddy, Bernadette Coles, Philipp Dahm
Affiliations
Meta-Analysis

Primary cryotherapy for localised or locally advanced prostate cancer

Jae Hung Jung et al. Cochrane Database Syst Rev. .

Abstract

Background: Traditionally, radical prostatectomy and radiotherapy with or without androgen deprivation therapy have been the main treatment options to attempt to cure men with localised or locally advanced prostate cancer. Cryotherapy is an alternative option for treatment of prostate cancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective this is in comparison to other treatments.

Objectives: To assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localised (cT1-T2) or locally-advanced (cT3) non-metastatic prostate cancer.

Search methods: We updated a previously published Cochrane Review by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries (ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform) and a grey literature repository (Grey Literature Report) up to 6 March 2018. We also searched the reference lists of other relevant publications and conference proceedings. We applied no language restrictions.

Selection criteria: We included randomised or quasi-randomised trials comparing cryotherapy to other interventions for the primary treatment of prostate cancer.

Data collection and analysis: Two independent reviewers screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the quality of evidence (QoE) according to the GRADE approach.

Main results: We included only one comparison of whole gland cryotherapy versus external beam radiotherapy, which was informed by two trials with a total of 307 randomised participants. The median age of the included studies was around 70 years. The median follow-up of included studies ranged from 100 to 105 months.Primary outcomes: we are uncertain about the effect of whole gland cryotherapy compared to radiation therapy on time to death from prostate cancer; hazard ratio (HR) of 1.00 (95% confidence interval (CI) 0.11 to 9.45; 2 trials, 293 participants; very low QoE); this would correspond to zero fewer death from prostate cancer per 1000 men (95% CI 85 fewer to 520 more). We are equally uncertain about the effect of quality of life-related urinary function and bowel function (QoL) at 36 months using the UCLA-Prostate Cancer Index score for which higher values (range: 0 to 100) reflect better quality of life using minimal clinically important differences (MCID) of 8 and 7 points, respectively; mean difference (MD) of 4.4 (95% CI -6.5 to 15.3) and 4.0 (95% CI -73.96 to 81.96), respectively (1 trial, 195 participants; very low QoE). We are also uncertain about sexual function-related QoL using a MCID of 8 points; MD of -20.7 (95% CI -36.29 to -5.11; 1 trial, 195 participants; very low QoE). Lastly, we are uncertain of the risk for major adverse events; risk ratio (RR): 0.91 (95% CI 0.47 to 1.78; 2 trials, 293 participants; very low QoE); this corresponds to 10 fewer major adverse events per 1000 men (95% CI 58 fewer to 86 more).

Secondary outcomes: we are very uncertain about the effects of cryotherapy on time to death from any cause (HR 0.99, 95% CI 0.05 to 18.79; 2 trials, 293 participants; very low QoE), and time to biochemical failure (HR 2.15, 95% CI 0.07 to 62.12; 2 trials, 293 participants; very low QoE). Rates of secondary interventions for treatment failure and minor adverse events were either not reported in the trials, or the data could not be used for analyses.We found no trials that compared whole gland cryotherapy or focal cryotherapy to other treatment forms such as radical surgery, active surveillance, watchful waiting or other forms of radiotherapy.

Authors' conclusions: Based on very low quality evidence, primary whole gland cryotherapy has uncertain effects on oncologic outcomes, QoL, and major adverse events compared to external beam radiotherapy. Reasons for downgrading the QoE included serious study limitations, indirectness due to the use of lower doses of radiation in the comparison group than currently recommended, and serious or very serious imprecision.

PubMed Disclaimer

Conflict of interest statement

JHJ: none known.

MCR: none known.

RG: none known.

BR: none known.

BC: none known.

PD: none known.

Figures

1
1
Flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 1 Time to death from prostate cancer.
1.2
1.2. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 2 Quality of life (at 3 months follow‐up).
1.3
1.3. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 3 Quality of life (at 36 months follow‐up).
1.4
1.4. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 4 Major adverse events.
1.5
1.5. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 5 Time to death from any cause.
1.6
1.6. Analysis
Comparison 1 Cryotherapy versus EBRT, Outcome 6 Time to biochemical failure.
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Chin 2008 {published data only}
    1. Al‐Zahrani A, Yutkin V, Autran A, Izawa J, Chin J. Long‐term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c‐T3b). Urology 2012;80(3):S271. - PubMed
    1. Al‐Zahrani AA, Autran AM, Williams A, Bauman G, Chin JL. Long‐term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c‐T3b). European Urology Supplements 2011;10(2):52. - PubMed
    1. Al‐zahrani A, Autran AM, Williams A, Bauman G, Izawa J, Chin J. Long‐term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c‐T3b). Journal of Urology 2011;185 (4 Suppl):e258. - PubMed
    1. Al‐zahrani AA, Autran Gomez A, Williams A, Bauman G, Izawa J, Chin J. Long‐term outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2C‐T3B). Journal of Clinical Oncology 2011;29(7 Suppl 1):78. - PubMed
    1. Chin JL, Al‐Zahrani AA, Autran‐Gomez AM, Williams AK, Bauman G. Extended follow up oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c‐T3b). Journal of Urology 2012;188(4):1170‐5. [DOI: 10.1016/j.juro.2012.06.014] - DOI - PubMed
Donnelly 2010 {published data only}
    1. Donnelly BJ, Saliken JC, Brasher P, Ernst S, Lau H, Trypkov K. A randomised controlled trial comparing external beam radiation and cryoablation in localised prostate cancer. Journal of Urology 2007;177(4):376‐7.
    1. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116(2):323‐30. [DOI: 10.1002/cncr.24779] - DOI - PubMed
    1. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Journal of Endourology 2010;24(8):1217‐8. - PubMed
    1. Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115(20):4695‐704. [DOI: 10.1002/cncr.24523] - DOI - PubMed

References to studies excluded from this review

Aus 2002 {published data only}
    1. Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5‐year follow‐up of a prospective study. European Urology 2002;42(2):133‐8. - PubMed
Bahn 2002 {published data only}
    1. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7‐year outcomes in the primary treatment of prostate cancer. Urology 2002;60(2 Suppl 1):3‐11. - PubMed
Cohen 1996 {published data only}
    1. Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two‐year prostate‐specific antigen and biopsy results. Urology 1996;47(3):395‐401. - PubMed
Coogan 1995 {published data only}
    1. Coogan CL, McKiel CF. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. Journal of Urology 1995;154(5):1813‐7. - PubMed
Donnelly 2002a {published data only}
    1. Donnelly BJ, Saliken JC, Ernst DS, Ali‐Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: five‐year results. Urology 2002;60:645‐9. - PubMed
Gould 1999 {published data only}
    1. Gould RS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. Journal of Urology 1999;162(5):1653‐7. - PubMed
Liu 2016 {published data only}
    1. Liu YY, Chiang PH. Comparisons of oncological and functional outcomes between primary whole‐gland cryoablation and high‐intensity focused ultrasound for localized prostate cancer. Annals of Surgical Oncology 2016;23:328‐34. [DOI: 10.1245/s10434-015-4686-x] - DOI - PubMed
Long 1998 {published data only}
    1. Long JP, Fallick ML, LaRock DR, Rand W. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. Journal of Urology 1998;159(2):477‐84. - PubMed
Prepelica 2005 {published data only}
    1. Prepelica KL, Okeke Z, Murphy A, Katz AE. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 2005;103(8):1625‐30. - PubMed
Wong 1997 {published data only}
    1. Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer 1997;79(5):963‐74. - PubMed

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365‐76. - PubMed
Albertsen 1995
    1. Albertsen P C, Fryback D G, Storer B E, Kolon T F, Fine J. Long‐term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274(8):626‐31. - PubMed
Arnott 1851
    1. Arnott J. On the Treatment of Cancer by the Regulated Application of an Anaesthetic Temperature. London (UK): Churchill, 1851:32‐54.
ASTRO Consensus Panel 1997
    1. ASTRO Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. International Journal of Radiation Oncology, Biology, Physics 1997;35:1035. - PubMed
AUA 2017
    1. American Urological Association. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. www.auanet.org/guidelines/clinically‐localized‐prostate‐cancer‐new‐(aua/... (accessed 20 August 2017).
Babaian 2008
    1. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. Journal of Urology 2008;180:1993‐2004. - PubMed
Barqawi 2014
    1. Barqawi AB, Stoimenova D, Krughoff K, Eid K, O'Donnell C, Phillips JM, et al. Targeted focal therapy for the management of organ confined prostate cancer. Journal of Urology 2014;192(3):749‐53. - PubMed
Baust 2004
    1. Baust JG, Gage AA, Clarke D, Baust JM, Buskirk R. Cryosurgery‐‐a putative approach to molecular‐based optimization. Cryobiology 2004;48:190‐204. - PubMed
Baust 2005
    1. Baust JG, Gage AA. The molecular basis of cryosurgery. BJU International 2005;95:1187‐91. - PubMed
Bedard 2014
    1. Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, et al. Minimal important differences in the EORTC QLQ‐C30 in patients with advanced cancer. Asia Pacific Journal of Clinical Oncology 2014;10(2):109‐17. - PubMed
Beerlage 2003
    1. Beerlage HP. Alternative therapies for localized prostate cancer. Current Urology Reports 2003;4:216‐20. - PubMed
Cohen 2004
    1. Cohen JK. Cryosurgery of the prostate: techniques and indications. Reviews in Urology 2004;6 Suppl 4:S20‐6. - PMC - PubMed
Cooper 2001
    1. Cooper SM, Dawber RP. The history of cryosurgery. Journal of the Royal Society of Medicine 2001;94:196‐201. - PMC - PubMed
Covidence [Computer program]
    1. Veritas Health Innovation. Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed 14 March 2018).
D'Amico 2003
    1. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer‐specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate‐specific antigen era. Journal of Clinical Oncology 2003;21:2163‐72. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Dickinson 2013
    1. Dickinson L, Ahmed HU, Kirkham AP, Allen C, Freeman A, Barber J, et al. A multi‐centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. Contemporary Clinical Trials 2013;36(1):68‐80. - PMC - PubMed
Donnelly 2002b
    1. Donnelly BJ, Saliken JC. Salvage cryosurgery ‐ how I do it. Reviews in Urology 2002;4 Suppl 2:S24‐9. - PMC - PubMed
D’Amico 2008
    1. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 2008;299(3):289–295. - PubMed
EAU 2017
    1. European Association of Urology. Prostate cancer (EAU guideline). uroweb.org/guideline/prostate‐cancer (accessed 20 August 2017).
EndNote [Computer program]
    1. Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016.
Gage 1998
    1. Gage AA. History of cryosurgery. Seminars in Surgical Oncology 1998;14:99‐109. - PubMed
Ganzer 2017
    1. Ganzer R, Hadaschik B, Pahernik S, Koch D, Baumunk D, Kuru T, et al. Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. Journal of Urology 2017 Oct 26 [Epub ahead of print]. - PubMed
Gao 2016
    1. Gao L, Yang L, Qian S, Tang Z, Qin F, Wei Q, et al. Cryosurgery would be an effective option for clinically localized prostate cancer: a meta‐analysis and systematic review. Scientific Reports 2016;6:27490. - PMC - PubMed
GRADEproGDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEproGDT. Version accessed 20 August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE] - DOI - PMC - PubMed
Guyatt 2011a
    1. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. - PubMed
Guyatt 2011b
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026] - DOI - PubMed
Hamdy 2016
    1. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10‐year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 2016;375(15):1415‐24. - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [DOI: 10.1002/sim.1186] - DOI - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557] - DOI - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011c
    1. Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011d
    1. Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jayadevappa 2012
    1. Jayadevappa R, Malkowicz SB, Wittink M, Wein AJ, Chhatre S. Comparison of distribution‐ and anchor‐based approaches to infer changes in health‐related quality of life of prostate cancer survivors. Health Services Research 2012;47(5):1902‐25. - PMC - PubMed
Jemal 2011
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a Cancer Journal for Clinicians 2011;61:69‐90. - PubMed
Johnston 2010
    1. Johnston BC, Thorlund K, Schunemann HJ, Xie F, Murad MH, Montori VM, et al. Improving the interpretation of quality of life evidence in meta‐analyses: the application of minimal important difference units. Health and Quality of Life Outcomes 2010;8:116. - PMC - PubMed
Koukourakis 2009
    1. Koukourakis G, Kelekis N, Armonis V, Kouloulias V. Brachytherapy for prostate cancer: a systematic review. Advances in Urology 2009. [DOI: 10.1155/2009/327945; Article ID: 327945] - DOI - PMC - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] - DOI - PMC - PubMed
Litwin 1998
    1. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health‐related quality of life measure. Medical Care 1998;36(7):1002‐12. - PubMed
Mariotto 2014
    1. Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. Journal of the National Cancer Institute Monographs 2014;49:145‐86. - PMC - PubMed
McCulloch 2009
    1. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009;374(9695):1105‐12. - PubMed
National Cancer Institute
    1. National Cancer Institute. Common Toxicity Criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed 23 August 2017).
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Rees 2004
    1. Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU International 2004;93:710‐4. - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roach 2006
    1. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics 2006;65(4):965‐74. - PubMed
Robinson 2002
    1. Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60:12‐8. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shelley 2007
    1. Shelley M, Wilt TJ, Coles B, Mason MD. Cryotherapy for localised prostate cancer. Cochrane Database of Systematic Reviews 2007, Issue 18. [DOI: 10.1002/14651858.CD005010.pub2] - DOI - PubMed
Tay 2016
    1. Tay KJ, Polascik TJ. Focal cryotherapy for localized prostate cancer. Archivos Españoles de Urología 2016;69(6):317‐26. - PubMed
Thompson 2007
    1. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby‐Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. Journal of Urology 2007;177:2106‐31. - PubMed
USCS Group 2014
    1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999 ‐ 2011 Incidence and Mortality Web‐based Report. nccd.cdc.gov/uscs. Altanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, (accessed 28 September 2017).
Valerio 2014
    1. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. European Urology 2014;66(4):732‐51. - PMC - PubMed
Xiong 2014
    1. Xiong T, Turner RM, Wei Y, Neal DE, Lyratzopoulos G, Higgins JP. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta‐analysis. BMJ Open 2014;4(5):e004285. - PMC - PubMed

Publication types

LinkOut - more resources